{"product_id":"9780470293423","title":"BACE Lead Target for Orchestrated Therapy of Alzheimer's Disease","description":"\u003ch1\u003eBACE\u003c\/h1\u003e\u003ch2\u003eLead Target for Orchestrated Therapy of Alzheimer's Disease\u003c\/h2\u003e\u003ch3\u003eVarghese John\u003c\/h3\u003e\u003cdiv\u003e\u003cb\u003eMedical \/ Pharmacology\u003c\/b\u003e\u003c\/div\u003e\u003cbr\u003e\u003cdiv\u003e\n\u003cp\u003e\u003cb\u003eBACE inhibitors and their use in the treatment of Alzheimer's Disease\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eBACE (β-site of APP cleaving enzyme) is a critical component in Alzheimer's Disease (AD), and the development of BACE inhibitors shows great potential as a therapy for the disease. \u003ci\u003eBACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease\u003c\/i\u003e covers virtually all aspects of BACE from initial identification, discovery of inhibitors, and challenges in clinical development, while providing a global understanding essential for productive and successful drug discovery.\u003c\/p\u003e \u003cp\u003eThis book details the story of the discovery of BACE and its role in AD and comprehensively discusses:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eThe development of BACE inhibitors as therapeutics for Alzheimer's disease\u003c\/li\u003e \u003cli\u003eThe research that led to the identification of BACE\u003c\/li\u003e \u003cli\u003eNew BACE inhibitors currently being clinically tested\u003c\/li\u003e \u003cli\u003eADME (absorption, distribution, metabolism, excretion) and clinical trial design—topics not addressed in current field literature\u003c\/li\u003e \u003cli\u003eCutting-edge technology such as high-throughput screening, structure-based drug design, and QSAR in context of BACE inhibitors and Alzheimer's drug discovery\u003c\/li\u003e \u003cli\u003eOther approaches to BACE inhibition based on interaction with the precursor protein APP\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eBy enhancing the reader's understanding of the various aspects of the BACE drug-discovery process, this much-needed reference will serve as a key resource for all scientists involved in Alzheimer's research—and inspire new approaches to treatment of AD.\u003c\/p\u003e\n\u003c\/div\u003e\u003cdiv\u003e \u003cp\u003e\u003cb\u003eVARGHESE JOHN\u003c\/b\u003e is Director of Alzheimer's Drug Discovery at the Buck Institute for Age Research. He is a chemist with many years of pharmaceutical industry experience in discovery and development of drugs for CNS diseases with a primary focus on Alzheimer's disease (AD). Dr. John has many publications and patents to his credit.\u003c\/p\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublication Date: \u003c\/td\u003e\n\u003ctd\u003e15 March 2010\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublisher: \u003c\/td\u003e\n\u003ctd\u003eWiley\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImprint: \u003c\/td\u003e\n\u003ctd\u003eWiley\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eISBN-13: \u003c\/td\u003e\n\u003ctd\u003e9780470293423\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormat: \u003c\/td\u003e\n\u003ctd\u003eHardback\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePage Count: \u003c\/td\u003e\n\u003ctd\u003e282\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeight (oz): \u003c\/td\u003e\n\u003ctd\u003e19.36\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":44379942486156,"sku":"9780470293423","price":133.16,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0710\/9545\/1788\/files\/9780470293423.jpg?v=1780281183","url":"https:\/\/fh90cf-fv.myshopify.com\/products\/9780470293423","provider":"Late Knight Books and Services, LLC","version":"1.0","type":"link"}